KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Gross Margin (2017 - 2025)

Biomarin Pharmaceutical's Gross Margin history spans 16 years, with the latest figure at 68.47% for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 1331.0% year-over-year to 68.47%, compared with a TTM value of 77.73% through Dec 2025, down 194.0%, and an annual FY2025 reading of 77.73%, down 194.0% over the prior year.
  • Gross Margin for Q4 2025 was 68.47% at Biomarin Pharmaceutical, down from 81.95% in the prior quarter.
  • The five-year high for Gross Margin was 81.95% in Q3 2025, with the low at 68.47% in Q4 2025.
  • Average Gross Margin over 5 years is 77.24%, with a median of 77.38% recorded in 2022.
  • Year-over-year, Gross Margin soared 1427bps in 2021 and then tumbled -1331bps in 2025.
  • Tracing BMRN's Gross Margin over 5 years: stood at 73.38% in 2021, then fell by -1bps to 72.72% in 2022, then increased by 8bps to 78.66% in 2023, then grew by 4bps to 81.78% in 2024, then decreased by -16bps to 68.47% in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Gross Margin are 68.47% (Q4 2025), 81.95% (Q3 2025), and 81.82% (Q2 2025).